Pat
Branford, HCCA Consumer Representative, attended the National Prescribing Service (NPS) MedicineWise
National Medicines Symposium in late 2014 which was held over three days. The
theme of the conference was ‘Medicines in Health: Shaping Our Future’.
Here is a
summery on the second day. To read more about the other two days of the
conference, click here.
Day 2 Plenary 2 – Sustainability
For these
plenary sessions the theme was about exploring the future in terms of cost,
benefit, access, quality and safety and investment in an increasingly
competitive health environment with a focus on sustainability.
Sustainability
and innovation – can we actually afford medicines – Professor Ian Frazer, CEO
and Director of Research, Translational Research Institute
The main
points discussed were:
·
Research
priority is determined by a person’s interest and is not dictated by government
interest;
·
The
longer we live the less likely we are to be healthy and as we age we use the
health system increasingly more;
·
As
a community of connectedness (i.e. via social media/internet) you know what
other healthy communities are receiving in terms of health care and you know
that you are not getting it and you want it;
·
The
need to meet consumer demand and treat non-infectious chronic conditions
increases as we age;
·
Whether
a person receives optimal health care is determined by a persons’ ability to
pay i.e. it is determined by their income and it is not a right i.e. it is not
a universal health care system; and
·
There
is a stringent need for safety regarding medications however, the cost of new
medications are past onto patients.
Cost and value: a consumer perspective
– What rights do I have? What should I be
able to expect? How are my expectations and values recognised? Durhane Wong
– Rieger, President and CEO, the Institute for Optimizing Health Outcomes, Canada
Durhane saw
the role of a consumer as being:Durhane saw
the role of a consumer in relation to medications as being:
Appropriate
access to medications:
·
An
assessment of benefits, risks, range of patient trade-offs;
·
Medications
need to be personalised – i.e. right medication, right patient, right time;
·
Regulatory
uncertainty of medication balanced by post market surveillance.
Responsible
access to medications:
·
Taking
medications as prescribed;
·
Monitor
for adverse effects; and
·
Feedback
on real – world effectiveness.
Sustainable
access to medications:
·
Affordable
cost to patients (i.e. co-payment);
·
Pricing
based on comparative value (two systems); and
·
Sufficient
return on investment – so there is an incentive for innovation.
Irresponsible
use of medications is unsustainable and costs over 9% of the health expenditure
or $500B globally on irresponsible use of medications and there is
approximately 54% non adherence to medication use.
Patient
Self-Funding of High-Cost Medications – what are the ethical issues? Dr Jennie Louise,
University of Adelaide
Arguments
for self funding of high-cost medications are:
·
Respect
for patients autonomy:
o
Patient
is in the best position to determine the merits for themselves; and
o
Not
giving patients information is paternalistic.
·
Patients
should be given information that they would deem to be relevant or they would
care to know about.
·
There
were some reasons for caution given:
·
Patients
may not be best placed to evaluate complex evidence regarding effectiveness of
the medication;
·
(generalisations
were made) that most patients are desperate and vulnerable;
·
(generalisations
were made) that most patients are not in a position to objectively weigh
information; and
·
Doctors
may influence decisions even if they are not trying to.
There
could/would be great variability in patient’s circumstances:
·
Disease
and prognosis would differ between patients;
·
Treatment
whilst evidence based, the likelihood of benefit, toxicity and side effects
could well be different; and
·
A
patient’s non-medical circumstances, goals and concerns would also need to be
taken into account.
The
unintended negative consequences for social and health systems are;
·
More
pressure by patients, groups/public to fund no-cost effective medications
·
Undermining
bargaining power of giants; and
·
Creating
additional costs to the public system.
Monitoring
for toxicity, treatment side effects, longer consultation times, administration
of medication will drive up the costs.
Equity
considerations
·
Particularly
important for the public system;
·
Inequitable
more affluent patients can access treatment not available to others in their
home state; and
·
Rural
customers can’t access treatment at all.
Other
sources of inequity
·
Could
lead to distortions in health care funding that further adds to inequity; and
·
May
have to pay for health care beyond basic health care.
Suggestions
·
Cost
sharing by paying 50% of the medication;
·
‘patient
advocate’ make a more autonomous decision i.e. impartial third party.
·
Defensible
presumption against self; and
·
HCCA
could be a patient advocate but I was told that they would need skills to determine
what patients want.
Chronic Conditions, financial burden
and pharmaceutical pricing: insights from Australian Consumers Associate
Professor Jennifer Whitty, School of Medicine, Griffith University; School
of Pharmacy, The University of Queensland
·
Prescription
medication (Pharmaceutical Benefit Scheme - PBS) spending was approximately
A$10.1 Billion pa in 2011/12;
·
Consumers
(patients) fund approximately 17% -
A$1.7 Billion pa;
·
Australians
median (average) out of pocket prescription costs are $199 pa; and
·
Patients
don’t fill prescriptions because of the cost.
Findings
re Financial Burden – Aggravating Factors
·
dose,
administration, aids, Webster packs all equal additional costs;
·
once
cease employment medication costs too much money; and
·
lack
of consistency between pharmacies and costs of medications.
Consequences
·
reduced
adherence to taking medications because of the cost;
·
stockpiling
of medications by some patients;
·
cost
displaces luxuries (example given was cigarettes); and
·
not
working so patients can get a health care card and get medications cheaper.
Understanding
and beliefs related to pharmaceutical pricing
·
relief
of costs can be obtained by either and/or having a health care card and the safety
net;
·
access
to medications not on the PBS in chronic conditions is an extra cost; and
·
fairness
is an issue as a patient you have paid your taxes and you are not to blame for
your condition but you have to pay high costs for your medication.
Conclusion
·
Australian
consumers with chronic conditions and carers perceive there is a financial
burden associated with medication use; and
·
This
financial cost is compounded by the ongoing need for medical care and
medication.
Dementia and care transitions: actions
to translate data and knowledge into practice – Professor
Gabrielle Cooper, Discipline of Pharmacy, University of Canberra
·
It
is illegal to do research on
dementia care patients in the ACT.
Issue of
Identity
·
Lack
of timely and accurate information sharing between the range of providers
(GP/hospital/pharmacy/RACF);
·
Lack
of awareness by a range of clinical staff of a patients possible dementia
diagnosis e.g. ED, X-Ray, orthopaedics, pharmacy, support staff;
·
Inconsistent
use/type of medication supports e.g. dose, administration aids;
·
Limited
access to appropriate trained support staff to assist or just assist in
settling patients; and
·
Hospital
pharmacies have different alignment of Webster care packs.
Other
points
·
Need
to settle patients – calm considered approach. Dementia training also required
for pharmacy staff and meals person;
·
There
are medication discrepancies between care settings which aren’t reconciled and
recommendations aren’t being followed up on due to lack of documentation and
communication strategies e.g. need transition medication charts;
·
Lack
of after hour support for families and small facilities to avoid acute
readmissions. Graduate nurses could go with a patient to a facility/hospital to
help settle a patient in;
·
Best
practice was centred on individual champions – GPPAD ACT.
Pat Branford
HCCA
Consumer Representative